Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
Investors
Media Coverage
NASDAQ: ENVB
Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Media Coverage
Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally [Benzinga]
July 25, 2024
BUSINESSPUBLIC Enveric bets on trip-free mental health drug for FDA approval hopes [Green Market Report]
June 25, 2024
Psychedelic Community Reacts To FDA Committee’s Critique Of Lykos’ MDMA Studies [Clinical Leader]
June 14, 2024
Psychedelics companies see FDA panel’s vote as a growth opportunity, not a roadblock [Stat News]
June 6, 2024
Enveric, MindBio partner to advance psilocin prodrugs for mental health disorders [Healio]
May 21, 2024
Rx Rundown: Sanofi, Bayer, Sands Capital and more [MMM]
May 17, 2024
‘Psychedelics-Inspired’ Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand [Benzinga]
May 16, 2024
Major deals continue positive trajectory for psychedelics in 2024 [Psychedelic Health]
May 16, 2024
$6M bankrolls Enveric pipeline partnering, depression program [Green Market Report]
May 15, 2024
Psychedelics for Depression: MindBio and Enveric’s Joint Efforts [TDR]
May 15, 2024
‹
1
2
3
4
5
…
13
›
Close Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
